ZIVO Zivo Bioscience, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1101026 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY164.5%
TTM net income YoY38.0%
TTM EPS YoY45.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin31.7%
Operating margin-4,045.7%
Net margin-4,059.7%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,608.6%
ROIC (approx.)—
Asset turnover0.40x
Leverage & solvency
Liabilities / assets687.5%
Debt / equity—
Current ratio0.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-1,025.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $65,625 | $53,400 | $0 | $90,000 | $31,500 | $0 | $35,720 | $11,800 |
| Cost of revenue | $44,337 | $35,478 | $0 | $63,000 | $22,050 | $0 | $23,218 | $7,669 |
| Gross profit | $21,288 | $17,922 | $0 | $27,000 | $9,450 | $0 | $12,502 | $4,131 |
| R&D expense | $203,444 | $479,657 | $2.77M | $243,483 | $326,361 | $2.25M | $312,767 | $312,465 |
| SG&A expense | $836,187 | $1.17M | $1.44M | $1.38M | $1.94M | $5.98M | $975,574 | $1.59M |
| Operating income | -$1.02M | -$1.63M | -$4.21M | -$1.60M | -$2.26M | -$8.23M | -$1.28M | -$1.90M |
| Interest expense | $12,959 | $7,360 | $2,400 | — | $8,560 | $6,766 | $2,647 | -$43,705 |
| Income tax | — | — | — | — | $0 | $0 | $0 | — |
| Net income | -$1.03M | -$1.64M | -$4.21M | -$1.60M | -$2.27M | -$8.24M | -$1.28M | -$1.91M |
| EPS (diluted) | -0.27 | -0.43 | -1.12 | — | -0.67 | -2.78 | -0.47 | — |
| Weighted avg. shares (diluted) | 3.82M | 3.81M | 3.75M | — | 3.41M | 2.96M | 2.75M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $57,222 | $9,823 | $517,189 | $1.54M | $159,403 | $2,466 | $138,641 | $274,380 |
| Current assets | $281,399 | $409,894 | $1.02M | $1.64M | $436,545 | $495,127 | $710,617 | $425,377 |
| PP&E, net | — | — | — | — | — | — | — | $0 |
| Total assets | $559,452 | $703,327 | $1.33M | $1.64M | $495,587 | $575,588 | $816,396 | $555,715 |
| Current liabilities | $3.61M | $2.96M | $2.61M | $2.04M | $2.58M | $2.87M | $3.09M | $2.76M |
| Short-term debt | — | — | $254,454 | $0 | — | — | — | $0 |
| Total liabilities | $3.85M | $3.24M | $2.95M | $2.16M | $2.58M | $2.87M | $3.09M | $2.76M |
| Shareholders' equity | -$3.29M | -$2.54M | -$1.62M | -$514,898 | -$2.08M | -$2.30M | -$2.27M | -$2.21M |
| Shares outstanding | 3.83M | 3.82M | 3.79M | 3.62M | 3.49M | 3.32M | 2.79M | 2.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$266,556 | -$476,410 | -$1.43M | -$905,722 | -$1.09M | -$623,654 | -$1.70M | -$715,733 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $313,955 | -$30,956 | $404,985 | $2.29M | $1.24M | $487,479 | $1.56M | -$494,530 |
| Stock-based compensation | — | — | — | — | — | — | — | -$621,159 |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.